Results 91 to 100 of about 2,116,504 (346)

Strategy for Engagement with Foundations [PDF]

open access: yes, 2012
The strategy for engagement with philanthropic foundations was adopted by UNDP senior management in July 2012. This strategy aims to reposition and strengthen UNDP's work with foundations vis a vis the new developments in the philanthropic sector and ...

core  

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau   +8 more
wiley   +1 more source

The Development of Employers’ Training Investments Over Time – A Decomposition Analysis Using German Establishment Data [PDF]

open access: yes
Using establishment data covering the time period 1997 to 2007, this paper investigates trends of employer-sponsored further training in Germany, with a focus on the share of establishments investing in training.
Katja Goerlitz
core  

Pharmaceutical M&A Activity: Effects on Prices, Innovation, and Competition [PDF]

open access: yes, 2017
The rise of blockbuster pharmaceutical acquisitions has prompted fears that unprecedented market concentration will weaken competition. Two of the most prominent concerns focus on the upstream and downstream ends of the pharmaceutical industry: (1) the ...
Mitchell, Will   +3 more
core   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Examination of Long-Term Temperature Change in Türkiye: Comparative Evaluation of an Advanced Quartile-Based Approach and Traditional Trend Detection Methods

open access: yesAtmosphere
The fact that 2023 and subsequently 2024 were the hottest years in history makes it even more important to monitor temperature changes over time. In this study, trends in the mean, maximum, and minimum temperature data of 81 provinces in Türkiye were ...
Omer Levend Asikoglu   +3 more
doaj   +1 more source

The French defence industry in the knowledge management era: A historical overview and evidence from empirical data [PDF]

open access: yes
In the defence industry the recent development of ‘market for technology', the creation of new European high-technology companies as well as transformations in government agencies have conducted firms to reposition their technological and organisational ...
Christian Longhi   +3 more
core  

Business Startup and Cause Marketing in the Running Apparel Industry [PDF]

open access: yes, 2014
Entrepreneurship has been the backbone of the American economy since the penning of the Declaration of Independence. Small businesses help the United States prosper and help create jobs for the American people.
Barker, Zachary
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Molecular cancer prevention: Intercepting disease

open access: yesMolecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy